
A successful delivery platform could deliver curative gene‑therapy for PKD and other hereditary kidney disorders, reducing the need for dialysis and transplants for millions of patients, while demonstrating AI’s potential to accelerate biotech innovation.
Nephrogen, a biotech startup combining AI and gene‑editing delivery tech to target kidney disease, is raising a $4 million seed round to advance its delivery mechanism and drug into clinical studies anticipated in 2027.
Comments
Want to join the conversation?
Loading comments...